Biochemical bone turnover markers in diabetes mellitus - A systematic review

Bone

Volumn 82, Issue , 2016, Pages 69-78

  Starup Linde, Jakob ^a,b   Vestergaard, Peter ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bone; Bone turnover; Bone turnover markers; Diabetes mellitus; Diabetes treatment; Fracture

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; METFORMIN; PIOGLITAZONE; SCLEROSTIN; SOMATOMEDIN C; BIOLOGICAL MARKER;

ADULT; BONE DENSITY; BONE MINERALIZATION; BONE TURNOVER; CARBOXY TERMINAL SEQUENCE; CROSS LINKING; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; FRACTURE; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOLYSIS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ANIMAL; BONE REMODELING; METABOLISM; PHYSIOLOGY; PROCEDURES;

ANIMALS; BIOMARKERS; BONE REMODELING; BONE RESORPTION; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; HUMANS; LONGITUDINAL STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84954372616     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2015.02.019     Document Type: Review

References (68)

1. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis. Osteoporos Int 2007, 18:427-444.
2. Giangregorio L.M., Leslie W.D., Lix L.M., Johansson H., Oden A., McCloskey E., et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 2012, 27:301-308.
3. Starup-Linde J. Diabetes, biochemical markers of bone turnover, diabetes control, and bone. Front Endocrinol 2013, 4.
4. Starup-Linde J., Eriksen S.A., Lykkeboe S., Handberg A., Vestergaard P. Biochemical markers of bone turnover in diabetes patients - a meta-analysis, and a methodological study on the effects of glucose on bone markers. Osteoporosis Int 2014, 25:1697-1708.
5. P. Szulc, D.C. Bauer, R. Eastell, eds., Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism chapter 35, biochemical markers of bone turnover in osteoporosis (pages 297-306). Eighth Edition, Editor(s): Clifford J. Rosen ed., Print ISBN: 9781118453889, Online ISBN: 9781118453926, DOI: 10.1002/9781118453926, 19 JUL 2013.
6. Bjarnason N.H., Henriksen E.E., Alexandersen P., Christgau S., Henriksen D.B., Christiansen C. Mechanism of circadian variation in bone resorption. Bone 2002, 30:307-313.
7. Viljakainen H., Ivaska K.K., Paldanius P., Lipsanen-Nyman M., Saukkonen T., Pietilainen K.H., et al. Suppressed bone turnover in obesity: a link to energy metabolism? A case-control study. J Clin Endocrinol Metab 2014, 99:2155-2163.
8. Bazelier M.T., de Vries F., Vestergaard P., Herings R.M., Gallagher A.M., Leufkens H.G., et al. Risk of fracture with thiazolidinediones: an individual patient data meta-analysis. Front Endocrinol (Lausanne) 2013, 4:11.
9. Locatelli V., Bianchi V.E. Effect of GH/IGF-1 on bone metabolism and osteoporosis. Int J Endocrinol 2014, 2014:235060.
10. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gotzsche P.C., Ioannidis J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700.
11. Jiajue R., Jiang Y., Wang O., Li M., Xing X., Cui L., et al. Suppressed bone turnover was associated with increased osteoporotic fracture risks in non-obese postmenopausal Chinese women with type 2 diabetes mellitus. Osteoporos Int 2014, 25:1999-2005.
12. Neumann T., Lodes S., Kastner B., Franke S., Kiehntopf M., Lehmann T., et al. High serum pentosidine but not esRAGE is associated with prevalent fractures in type 1 diabetes independent of bone mineral density and glycaemic control. Osteoporos Int 2014, 25:1527-1533.
13. Ikeda T., Manabe H., Iwata K. Clinical significance of alendronate in postmenopausal type 2 diabetes mellitus. Diabetes Metab 2004, 30:355-358.
14. Zinman B., Haffner S.M., Herman W.H., Holman R.R., Lachin J.M., Kravitz B.G., et al. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab 2010, 95:134-142. ADOPT Study Group.
15. Lumachi F., Camozzi V., Tombolan V., Luisetto G. Bone mineral density, osteocalcin, and bone-specific alkaline phosphatase in patients with insulin-dependent diabetes mellitus. Ann N Y Acad Sci 2009, 1173(Suppl. 1):E64-E67.
16. Okazaki R., Miura M., Toriumi M., Taguchi M., Hirota Y., Fukumoto S., et al. Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J 1999, 46:795-801.
17. Bunck M.C., Poelma M., Eekhoff E.M., Schweizer A., Heine R.J., Nijpels G., et al. Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients. J Diabetes 2012, 4:181-185.
18. Berberoglu Z., Gursoy A., Bayraktar N., Yazici A.C., Tutuncu N.B., Demirag N.G. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 2007, 92:3523-3530.
19. Pater A., Sypniewska G., Pilecki O. Biochemical markers of bone cell activity in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2010, 23:81-86.
20. Jehle P.M., Jehle D.R., Mohan S., Bohm B.O. Serum levels of insulin-like growth factor system components and relationship to bone metabolism in type 1 and type 2 diabetes mellitus patients. J Endocrinol 1998, 159:297-306.
21. Inaba M., Okuno S., Kumeda Y., Yamakawa T., Ishimura E., Nishizawa Y. Increased incidence of vertebral fracture in older female hemodialyzed patients with type 2 diabetes mellitus. Calcif Tissue Int 2005, 76:256-260.
22. Bilezikian J.P., Josse R.G., Eastell R., Lewiecki E.M., Miller C.G., Wooddell M., et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013, 98:1519-1528.
23. Keegan T.H., Schwartz A.V., Bauer D.C., Sellmeyer D.E., Kelsey J.L. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. Diabetes Care 2004, 27:1547-1553. fracture intervention trial.
24. Bauer D., Krege J., Lane N., Leary E., Libanati C., Miller P., et al. National bone health alliance bone turnover marker project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int 2012, 23:2425-2433.
25. Sarkar P.D., Choudhury A.B. Relationships between serum osteocalcin levels versus blood glucose, insulin resistance and markers of systemic inflammation in central Indian type 2 diabetic patients. Eur Rev Med Pharmacol Sci 2013, 17:1631-1635.
26. Karaguzel G., Akcurin S., Ozdem S., Boz A., Bircan I. Bone mineral density and alterations of bone metabolism in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2006, 19:805-814.
27. Alexopoulou O., Jamart J., Devogelaer J.P., Brichard S., de Nayer P., Buysschaert M. Bone density and markers of bone remodeling in type 1 male diabetic patients. Diabetes Metab 2006, 32:453-458.
28. Hamilton E.J., Rakic V., Davis W.A., Paul Chubb S.A., Kamber N., Prince R.L., et al. A five-year prospective study of bone mineral density in men and women with diabetes: the Fremantle Diabetes Study. Acta Diabetol 2012, 49:153-158.
29. Armas L.A., Akhter M.P., Drincic A., Recker R.R. Trabecular bone histomorphometry in humans with type 1 diabetes mellitus. Bone 2012, 50:91-96.
30. Akin O., Gol K., Akturk M., Erkaya S. Evaluation of bone turnover in postmenopausal patients with type 2 diabetes mellitus using biochemical markers and bone mineral density measurements. Gynecol Endocrinol 2003, 17:19-29.
31. Reyes-Garcia R., Rozas-Moreno P., Lopez-Gallardo G., Garcia-Martin A., Varsavsky M., Aviles-Perez M.D., et al. Serum levels of bone resorption markers are decreased in patients with type 2 diabetes. Acta Diabetol 2013, 50:47-52.
32. Yamamoto M., Yamaguchi T., Nawata K., Yamauchi M., Sugimoto T. Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2012, 97:1277-1284.
33. Farr J.N., Drake M.T., Amin S., Melton L.J., McCready L.K., Khosla S. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res 2014, 29:787-795.
34. Manavalan J.S., Cremers S., Dempster D.W., Zhou H., Dworakowski E., Kode A., et al. Circulating osteogenic precursor cells in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012, 97:3240-3250.
35. Bhattoa H.P., Onyeka U., Kalina E., Balogh A., Paragh G., Antal-Szalmas P., et al. Bone metabolism and the 10-year probability of hip fracture and a major osteoporotic fracture using the country-specific FRAX algorithm in men over 50years of age with type 2 diabetes mellitus: a case-control study. Clin Rheumatol 2013, 32:1161-1167.
36. Gaudio A., Privitera F., Battaglia K., Torrisi V., Sidoti M.H., Pulvirenti I., et al. Sclerostin levels associated with inhibition of the Wnt/beta-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012, 97:3744-3750.
37. Ardawi M.S., Akhbar D.H., Alshaikh A., Ahmed M.M., Qari M.H., Rouzi A.A., et al. Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone 2013, 56:355-362.
38. Movahed A., Larijani B., Nabipour I., Kalantarhormozi M., Asadipooya K., Vahdat K., et al. Reduced serum osteocalcin concentrations are associated with type 2 diabetes mellitus and the metabolic syndrome components in postmenopausal women: the crosstalk between bone and energy metabolism. J Bone Miner Metab 2012, 30:683-691.
39. van Lierop A.H., Hamdy N.A., van der Meer R.W., Jonker J.T., Lamb H.J., Rijzewijk L.J., et al. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus. Eur J Endocrinol 2012, 166:711-716.
40. Sosa M., Dominguez M., Navarro M.C., Segarra M.C., Hernandez D., de Pablos P., et al. Bone mineral metabolism is normal in non-insulin-dependent diabetes mellitus. J Diabetes Complications 1996, 10:201-205.
41. Rozas Moreno P., Reyes Garcia R., Garcia-Martin A., Varsavsky M., Garcia-Salcedo J.A., Munoz-Torres M. Serum osteoprotegerin: bone or cardiovascular marker in type 2 diabetes males?. J Endocrinol Invest 2013, 36:16-20.
42. Jorgensen L., Vik A., Emaus N., Brox J., Hansen J.B., Mathiesen E., et al. Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromso Study. Osteoporos Int 2010, 21:931-938.
43. Catalano A., Pintaudi B., Morabito N., Di Vieste G., Giunta L., Bruno M.L., et al. Gender differences in sclerostin and clinical characteristics in type 1 diabetes mellitus. Eur J Endocrinol 2014, 171:293-300.
44. Register T.C., Hruska K.A., Divers J., Bowden D.W., Palmer N.D., Carr J.J., et al. Sclerostin is positively associated with bone mineral density in men and women and negatively associated with carotid calcified atherosclerotic plaque in men from the African American-Diabetes Heart Study. J Clin Endocrinol Metab 2014, 99:315-321.
45. Chen H., Li X., Yue R., Ren X., Zhang X., Ni A. The effects of diabetes mellitus and diabetic nephropathy on bone and mineral metabolism in T2DM patients. Diabetes Res Clin Pract 2013, 100:272-276.
46. Kanazawa I., Yamaguchi T., Yamamoto M., Yamauchi M., Yano S., Sugimoto T. Serum insulin-like growth factor-I level is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int 2007, 18:1675-1681.
47. Kanazawa I., Yamaguchi T., Sugimoto T. Serum insulin-like growth factor-I is a marker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int 2011, 22:1191-1198.
48. Yamamoto M., Yamauchi M., Sugimoto T. Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013, 98:4030-4037.
49. Kanazawa I., Yamaguchi T., Yamamoto M., Sugimoto T. Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. J Bone Miner Metab 2010, 28:554-560.
50. Yamamoto M., Yamaguchi T., Yamauchi M., Yano S., Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2008, 93:1013-1019.
51. Selby P.L., Shearing P.A., Marshall S.M. Hydroxyproline excretion is increased in diabetes mellitus and related to the presence of microalbuminuria. Diabet Med 1995, 12:240-243.
52. Hegazy S.K. Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women. J Bone Miner Metab 2014, 33(2):207-212.
53. Monami M., Dicembrini I., Antenore A., Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 2011, 34:2474-2476.
54. Gruntmanis U., Fordan S., Ghayee H.K., Abdullah S.M., See R., Ayers C.R., et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial. Calcif Tissue Int 2010, 86:343-349.
55. Nybo M., Preil S.R., Juhl H.F., Olesen M., Yderstraede K., Gram J., et al. Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients. Basic Clin Pharmacol Toxicol 2011, 109:481-485.
56. Xiao W.H., Wang Y.R., Hou W.F., Xie C., Wang H.N., Hong T.P., et al. The effects of pioglitazone on biochemical markers of bone turnover in the patients with type 2 diabetes. Int J Endocrinol 2013, 2013:290734.
57. Ljunggren O., Bolinder J., Johansson L., Wilding J., Langkilde A.M., Sjostrom C.D., et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2012, 14:990-999.
58. Hernandez J.L., Olmos J.M., Romana G., Martinez J., Castillo J., Yezerska I., et al. Bone turnover markers in statin users: a population-based analysis from the Camargo Cohort Study. Maturitas 2013, 75:67-73.
59. Braatvedt G.D., Bagg W., Gamble G., Davidson J., Reid I.R. The effect of atorvastatin on markers of bone turnover in patients with type 2 diabetes. Bone 2004, 35:766-770.
60. Rejnmark L., Vestergaard P., Mosekilde L. Statin but not non-statin lipid-lowering drugs decrease fracture risk: a nation-wide case-control study. Calcif Tissue Int 2006, 79:27-36.
61. Mori H., Okada Y., Kishikawa H., Inokuchi N., Sugimoto H., Tanaka Y. Effects of raloxifene on lipid and bone metabolism in postmenopausal women with type 2 diabetes. J Bone Miner Metab 2013, 31:89-95.
62. Vestergaard P., Rejnmark L., Mosekilde L. Are antiresorptive drugs effective against fractures in patients with diabetes?. Calcif Tissue Int 2011, 88:209-214.
63. Clowes J.A., Allen H.C., Prentis D.M., Eastell R., Blumsohn A. Octreotide abolishes the acute decrease in bone turnover in response to oral glucose. J Clin Endocrinol Metab 2003, 88:4867-4873.
64. Pramojanee S.N., Phimphilai M., Chattipakorn N., Chattipakorn S.C. Possible roles of insulin signaling in osteoblasts. Endocr Res 2014, 39(4):144-151.
65. Ferron M., Wei J., Yoshizawa T., Del Fattore A., DePinho R.A., Teti A., et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 2010, 142:296-308.
66. Ferron M., McKee M.D., Levine R.L., Ducy P., Karsenty G. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone 2012, 50:568-575.
67. Cunha J.S., Ferreira V.M., Maquigussa E., Naves M.A., Boim M.A. Effects of high glucose and high insulin concentrations on osteoblast function in vitro. Cell Tissue Res 2014, 358(1):249-256.
68. Xu F., Ye Y.P., Dong Y.H., Guo F.J., Chen A.M., Huang S.L. Inhibitory effects of high glucose/insulin environment on osteoclast formation and resorption in vitro. J Huazhong Univ Sci Technolog Med Sci 2013, 33:244-249.